Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02182035
Contributor : Laurent Jonchère <>
Submitted on : Friday, July 12, 2019 - 3:32:21 PM Last modification on : Thursday, January 14, 2021 - 11:22:48 AM
C. Soussain, S. Choquet, M. Blonski, D. Leclercq, C. Houillier, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer, Elsevier, 2019, 117, pp.121-130. ⟨10.1016/j.ejca.2019.05.024⟩. ⟨hal-02182035⟩